Scrip's Rough Guide To IDO
IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.
IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.